Clinical Trials Logo

Clinical Trial Summary

Most of asthmatics patients remain uncontrolled despite an inhaled steroids treatment. Chronic hyperventilation syndrome (also called Idiopathic Hyperventilation) occurs in 20 to 40% of asthmatic patients. The purpose of the study is to assess the prevalence of chronic hyperventilation syndrome in a specific population of difficult-to-treat asthmatics patients, those who receive daily high doses of inhaled steroids (≥ 1000 µg of fluticasone with an additional treatment by a long-acting beta 2-agonist (LABA) and who remain uncontrolled (Asthma control test (ACT) < 18). We plan to realize a systematic assessment of the diagnosis of chronic hyperventilation syndrome with the Nijmegen questionnaire, blood gases at rest, hyperventilation testing and Cardiopulmonary Exercise Testing(CPET). We also will collect demographic information as well as information about asthma history, asthma control and treatment.


Clinical Trial Description

There is only one visit. During this visit, each patient will complete self-questionnaires like Nijmegen, Hospital Anxiety and Depression Scale(HAD), Short-Form 36(SF36), and Asthma Quality of Life Questionnaire (AQLQ), The participants will have baseline spirometry and fractional exhaled nitric oxide measured at expiratory flow of 50 mL/s (FENO50), blood gases at rest, an hyperventilation challenge and Cardiopulmonary Exercise Testing(CPET) to determine accurately the presence or not of chronic hyperventilation syndrome. The diagnosis is confirmed by two positive tests (Nijmegen, Hyperventilation challenge and blood gases) and the final decision of a medical committee. The first step is to determine the prevalence oh this syndrome in this specific population. The second step is to assess the sensitivity, the specificity, the false positive rate and the false negative rate of the different parameters measured during the tests. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01862289
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Completed
Phase N/A
Start date April 28, 2013
Completion date October 18, 2016

See also
  Status Clinical Trial Phase
Terminated NCT01197482 - Inhaled Steroids and Control of Severe Asthma
Withdrawn NCT02952066 - Expressions of TRPV1 in Airway of Asthmatics N/A
Completed NCT02559791 - Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Phase 2/Phase 3
Recruiting NCT03617718 - Project 2 Airway Potential Hydrogen (pH) in Asthma Phase 1/Phase 2
Recruiting NCT01839591 - Bronchial Thermoplasty: Effect on Neuronal and Chemosensitive Component of the Bronchial Mucosa N/A
Withdrawn NCT00954850 - A National Program for Severe Asthma: The Canadian Severe Asthma Network N/A
Completed NCT01748175 - Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma
Withdrawn NCT01745809 - Bronchoscopy Study for Severe Asthma N/A
Completed NCT02717689 - A Pragmatic Trial of Corticosteroid Optimisation in Severe Asthma N/A
Completed NCT01750411 - Severe Asthma Research Program - Wake Forest University
Completed NCT02659618 - Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma
Withdrawn NCT00689806 - Evaluation of Lovastatin in Severe Persistent Asthma Phase 1/Phase 2